Regular Article

Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann–Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease

Yuta Tanaka,⁎,† Yusei Yamada,⁎,† Yoichi Ishitsuka,⁎ Muneaki Matsuo, Koki Shiraishi,⁎ Koki Wada,⁎ Yushihiro Uchio,⁎ Yuki Kondo,⁎ Toru Takeo, Naomi Nakagata, Taishi Higashi,⁎ Keiichi Motoyama,⁎ Hitotoshi Arima,⁎ Sakiko Mochinaga,⁎ Katsumi Higaki,⁎ Kousaku Ohno,⁎ and Tetsumi Irie⁎,†,‡,

a Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University; 5–1 Oe-honmachi, Chuo-ku, Kumamoto 862–0973, Japan; b Department of Pediatrics, Faculty of Medicine, Saga University; 5–1–1 Nabeshima, Saga 849–8501, Japan; c Research Institute, Nihon Shokuhin Kako Co., Ltd.; 30 Tajima, Fuji, Shizuoka 417–8530, Japan; d Division of Reproductive Engineering, Center for Animal Resources and Development (CARD), Kumamoto University; 2–2–1 Honjo, Chuo-ku, Kumamoto 860–0811, Japan; e Department of Pharmaceutical Physics, Graduate School of Pharmaceutical Sciences, Kumamoto University; 5–1 Oe-honmachi, Chuo-ku, Kumamoto 862–0973, Japan; f Department of Pharmacy, Faculty of Medicine, Saga University; 5–1–1 Nabeshima, Saga 849–8501, Japan; g Division of Functional Genomics, Research Center for Bioscience and Technology, Faculty of Medicine, Tottori University; 86 Nishi-cho, Yonago, Tottori 683–8503, Japan; and h Sanin Rosai Hospital; 1–8–1 Kaikeshinden, Yonago, Tottori 683–8605, Japan. Received October 20, 2014; accepted February 22, 2015

Niemann–Pick type C disease (NPC), an autosomal recessive lysosomal storage disorder, is an inherited disease characterized by the accumulation of intracellular unesterified cholesterol. A solubilizing agent of lipophilic compounds, 2-hydroxypropyl-β-cyclodextrin (HPBCD), is an attractive drug candidate against NPC disease. However, establishment of the optimum dosage of HPBCD remains to be determined. In this study, we evaluated the effective dosage of HPBCD in NPC model (Npc1−/−) mice, and determined serum HPBCD concentrations. Subcutaneous injection of 1000–4000 mg/kg HPBCD improved the lifespan of Npc1−/− mice. In addition, liver injury and cholesterol sequestration were significantly prevented by 4000 mg/kg HPBCD in Npc1−/− mice. Serum HPBCD concentrations, when treated at the effective dosages (1000–4000 mg/kg), were approximately 1200–2500 µg/mL at 0.5 h after subcutaneous injection, and blood HPBCD concentrations were immediately eliminated in Npc1−/− mice. Furthermore, we examined serum HPBCD concentrations when treated at 4000 mg (approximately 2500 mg/kg) in a patient with NPC. We observed that the effective concentration in the in vivo study using Npc1−/− mice was similar to that in the patient. In the patient, systemic clearance and the volume of distribution of HPBCD were in accordance with the glomerular filtration rate and extracellular fluid volume, respectively. These results could provide useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.

Key words Niemann–Pick type C; 2-hydroxypropyl-β-cyclodextrin; Npc1-deficient mouse

Niemann–Pick type C (NPC) disease is a fatal, progressive, and autosomal recessive disorder caused by mutations in either the NPC1 (95% of cases) or NPC2 gene. Symptoms of NPC disease include severe progressive neurodegeneration and enlargement of the liver. NPC1 protein, localized in late endosomes/lysosomes, has a sterol-sensing domain, and plays an important role in cellular cholesterol transport. Marked lysosomal accumulation of unesterified cholesterol and a shortage of esterified cholesterol in other cellular compartments are observed in the cells of NPC patients. Cholesterol sequestration appears to be an important factor in developing NPC disease. A cyclic oligosaccharide, 2-hydroxypropyl-β-cyclodextrin (HPBCD), is used as an enabling excipient in pharmaceutical formulations, as well as a cholesterol modifier in the body. Some reports have shown that HPBCD improves cholesterol sequestration in organs and prolongs the lifespan in Npc1 null mice, suggesting that HPBCD is a promising drug candidate against NPC disease.

Recently, Matsuo et al. reported the effectiveness of HPBCD in treatment of two Japanese patients with NPC disease. One patient was started with intravenous infusion of 80 mg/kg HPBCD for 8 h twice a week, and another patient was started with 80 mg/kg HPBCD for 8 h three times a week. This dose of HPBCD was gradually increased to approximately 2000 mg/kg or 2500 mg/kg. HPBCD was partially effective in improving hepatosplenomegaly and central nervous system dysfunction, although HPBCD did not improve their neurological deficits. However, little is known regarding pharmacokinetic information, such as effective serum HPBCD concentrations, systemic clearance, and volume of distribution, in NPC patients, and even in NPC model mice.

Pharmacodynamic and pharmacokinetic information is essential for establishing the appropriate dosage regimen of HPBCD for treatment of NPC. We conducted this study to evaluate the effective dose of HPBCD in NPC model mice, and determined serum HPBCD concentrations when the effective dose of HPBCD was administered to NPC model mice. Furthermore, we measured serum HPBCD concentrations...
during intravenous infusion in a patient with NPC, and also estimated the pharmacokinetic parameters of HPBCD.

MATERIALS AND METHODS

Reagents HPBCD (average degree of substitution [DS]: 4.7) that was used for mice experiments was kindly donated by Nihon Shokuhin Kakoh Co., Ltd. (Tokyo, Japan). HPBCD (Kleptose-HPB) that was used for intravenous treatment for a patient was purchased from Roquette Japan K.K. (Tokyo, Japan). A cholesterol detection reagent, Determiner L FC, was kindly donated by Kyowa Medex Co., Ltd. (Tokyo, Japan). A solution of 10% neutral buffered formalin was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Mayer’s hematoxylin, 1% eosin alcohol solution, and mounting medium for histological examination (malinol) were purchased from Muto Pure Chemicals (Tokyo, Japan). All other reagents and solvents were of reagent grade. De-ionized and distilled bio-pure grade water was used throughout the study.

Animal Experiments Male and female homozygous (Npc1−/−) mutant (BALB/cNctr−/−Npc1m1N) mice were used as NPC model mice. Age-matched wild-type (Npc1+/+) and heterozygous mutant (Npc1+/−) mice were used as control mice. Mice were housed in cages in a room under controlled conditions at 24°C with a 12-h light cycle, and provided with free access to food and water. A total of 168 Npc1−/−, 6 Npc1+/− and 6 Npc1+/+ mice were used in this study. The effects of HPBCD on manifestation of NPC in mice were evaluated by examining survival. We also performed biological and histological analyses, such as measurements of cholesterol content in the liver, relative liver weight to body weight, liver pathohistology, and serum alanine transaminase (ALT) levels. All experimental procedures conformed to the animal use guidelines of the Committee for Ethics on Animal Experiments of Kumamoto University (approval numbers M24-367 and F25-306). The mice were bred and kept in specific pathogen-free conditions in the Center for Animal Resources and Development, Kumamoto University. The animal experiments were performed at the Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University.

Effects of HPBCD on Survival in Npc1−/− Mice A total of 78 age-matched (6 weeks old) Npc1−/− mice were divided into the following six groups: (1) the saline group that was treated with saline (20µL/g) (n=6; 9 males and 7 females); (2) 400 mg/kg group that was treated with 400mg/kg of HPBCD (n=10; 5 males and 5 females); (3) 1000 mg/kg group that was treated with 1000mg/kg of HPBCD (n=12; 6 males and 6 females); (4) 2000 mg/kg group that was treated with 2000mg/kg of HPBCD (n=16; 8 males and 8 females); (5) 4000 mg/kg group that was treated with 4000mg/kg of HPBCD (n=10; 5 males and 5 females); and (6) 20000 mg/kg group that was treated with 20000mg/kg of HPBCD (n=14; 7 males and 7 females). HPBCD was dissolved in water and adjusted to pH 7.4. HPBCD was administrated by subcutaneous injection through the back of the neck in mice. The injection volume of HPBCD solution was set at 20µL/g in all of the HPBCD-treated groups. We measured the body weight of mice and treated the mice with HPBCD once a week during the life-span. The doses of 0−4000 mg/kg HPBCD used in this study were selected based on previous reports.2−9 In addition, the upper dose (20000mg/kg) of HPBCD does not have any adverse effects in acute toxicity in Npc1−/− mice, as found in our previous study.10

Effects of HPBCD on Biological and Histological Parameters in Npc1−/− Mice A total of 36 age-matched (6 weeks old) Npc1−/− mice were divided into the following six groups: (1) the saline group that was treated with saline (20µL/g) (n=6; 3 males and 3 females); (2) 400 mg/kg group that was treated with 400mg/kg of HPBCD (n=6; 3 males and 3 females); (3) 1000 mg/kg group that was treated with 1000mg/kg of HPBCD (n=6; 3 males and 3 females); (4) 2000 mg/kg group that was treated with 2000mg/kg of HPBCD (n=6; 3 males and 3 females); (5) 4000 mg/kg group that was treated with 4000mg/kg of HPBCD (n=6; 3 males and 3 females); and (6) 20000 mg/kg group that was treated with 20000mg/kg of HPBCD (n=6; 3 males and 3 females). We treated 6-week-old NPC mice with HPBCD or saline once a week until 8.5 weeks of age by subcutaneous injection (3 injections in total). The injection volume of HPBCD solution was set at 20µL/g in all of the HPBCD-treated groups. In addition, male and female age-matched (6 weeks old) Npc1−/− and Npc1+/− mice were used as controls. Finally, another two groups, the Npc1+/− saline group (n=6; 3 males and 3 females) and the Npc1−/− saline group (n=6; 3 males and 3 females), were included. These mice were treated with saline (20µL/g) once a week until 8.5 weeks of age by subcutaneous injection (3 injections in total).

Following the final injection, all of the mice were euthanized, and blood and organ samples were collected. Blood samples were collected from the inferior vena cava. The blood samples were centrifuged at 4000×g at 4°C for 10 min after coagulation, and serum was collected for measurement of ALT levels. Sera were stored at −30°C until further analysis. ALT levels were measured by a biochemical analyzer (Hitachi 7170, Hitachi, Tokyo, Japan).

Liver samples were immediately weighed and a portion of the hepatic lobes was immediately stored at −80°C until cholesterol measurements. Tissue homogenates were prepared in buffer (20 mM Tris, 2 mM ethylenediaminetetraacetic acid (EDTA), 150 mM NaCl, and 1% Triton-X-100, pH 8) and centrifuged for 10 min at 10000×g at 4°C. The supernatant was removed and the pellet was collected. The pellet was dissolved in phosphate buffered saline (PBS) and aliquoted into two samples. One aliquot was incubated with cholesterol esterase at 37°C for 30 min. The cholesterol content in these samples was measured by the Determiner L FC (Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan) according to the manufacturer’s protocol. Other hepatic lobes were immediately fixed in 10% neutral buffered formalin and then embedded in paraffin. Microtome sections, 3µm thick, were prepared and stained with hematoxylin–eosin (H&E). Histopathological changes in the liver were photographed and analyzed using a microscopic system (Biorevo BZ-9000; Keyence Co., Osaka, Japan). The results were evaluated in an unblinded manner. We also estimated the ratio of liver weight to body weight as a measure of enlargement of the liver.

Measurement of Serum HPBCD Concentrations in Npc1−/− Mice A total of 54 age-matched (8 weeks old) Npc1−/− mice were divided into three groups (1−3), with each group having three subgroups (A−C). (1-A) 1000mg/kg 0.5 h after group, where 1000mg/kg of HPBCD was administered.
and the concentration measured at 0.5 h after the treatment (n=6; male 3 and female 3); (1-B) 1000 mg/kg 1 h after group, where 1000 mg/kg of HPBCD was administered and the concentration measured at 1 h after the treatment (n=6; male 3 and female 3); (1-C) 1000 mg/kg 2 h after group, where 1000 mg/kg of HPBCD was administered and the concentration measured at 2 h after the treatment (n=6; male 3 and female 3); (2-A) 2000 mg/kg 0.5 h after group, where 2000 mg/kg of HPBCD was administered and the concentration measured at 0.5 h after the treatment (n=6; male 3 and female 3); (2-B) 2000 mg/kg 1 h after group, where 2000 mg/kg of HPBCD was administered and the concentration measured at 1 h after the treatment (n=6; male 3 and female 3); (2-C) 2000 mg/kg 2 h after group, where 2000 mg/kg of HPBCD was administered and the concentration measured at 2 h after the treatment (n=6; male 3 and female 3); (3-A) 4000 mg/kg 0.5 h after group, where 4000 mg/kg of HPBCD was administered and the concentration measured at 0.5 h after the treatment (n=6; male 3 and female 3); (3-B) 4000 mg/kg 1 h after group, where 4000 mg/kg of HPBCD was administered and the concentration measured at 1 h after the treatment (n=6; male 3 and female 3); (3-C) 4000 mg/kg 2 h after group, where 4000 mg/kg of HPBCD was administered and the concentration measured at 2 h after the treatment (n=6; male 3 and female 3). Mice were euthanized at each time of measurement and blood samples were collected from the inferior vena cava.

Blood samples were centrifuged at 4000 g at 4°C for 10 min and blood samples were collected from the inferior vena cava. After mixing and centrifugation, samples were centrifuged at 4°C for 10 min (10000×g) at 4°C for 10 min after coagulation, and serum was collected for measurement of HPBCD. HPBCD concentrations were determined by the procedure described in the next section.

Measurement of Serum HPBCD Concentrations in an NPC Patient We measured serum HPBCD concentrations in an NPC patient during intravenous HPBCD therapy. Detailed information of the patient and the therapeutic process have been previously described. In brief, the patient, a 4-year-old girl in whom hepatosplenomegaly was detected before birth, was diagnosed as having NPC based on mutations in the NPC1 gene (c.581_592delinsG, Y1088C). Hepatosplenomegaly was present before starting HPBCD intravenous therapy. The patient could walk indoors with assistance and speak a few clear words. She exhibited vertical gaze palsy, mild oculocutaneous dysphagia, slight hypotonia, ataxia and frequent attacks of cataplexy, and rare convulsions. HPBCD treatment was performed according to the Addi and Cassi HPBCD compassionate use clinical study protocol (Protocol Extension 1.0, 7 July 2009), kindly provided by Chris Hempel (http://addiandcassi.com/). HPBCD (Kleptose-HPB, Roquette Japan K.K.) was dissolved in distilled water at a concentration of 20% (w/v) and diluted to the required concentration with saline prior to infusion. HPBCD infusions were started after informed consent had been obtained from the parents. She initially had 80 mg/kg HPBCD per dose, infused over a period of 8 h, thrice weekly. This dose of HPBCD was gradually increased to approximately 2500 mg/kg per dose. As reported previously, intravenous treatment of HPBCD was effective in improving hepatosplenomegaly after 4 months of treatment.

Assessment of serum HPBCD concentrations was performed at 8 months of treatment. Blood samples were collected at 2, 8, and 12 h after the start of HPBCD infusion. This study was approved by the Ethics Committees of Saga University (no. 2009-05-04) and Kumamoto University (nos. 608 and 879). The therapeutic intervention was performed at Saga University Hospital.

Determination of Serum HPBCD Concentrations Measurement of serum HPBCD concentrations was performed according to the method reported by Frijlink et al. and Szathmary. The high-performance liquid chromatography (HPLC) equipment consisted of two LC-10AT pumps, an SIL-10A XL auto injector, an SPD-10A UV-Vis detector, a CBM-10A communications bus module, and a CTO-10AC column oven (Shimadzu Corporation, Kyoto, Japan). The HPLC column, OHpak SB-802 HQ (Showa Denko K.K., Tokyo, Japan), was used at 50°C. One LC10-A pump was used for delivering column eluent to the HPLC column and the other pump was for supply of post-column reagent after passing through the HPLC column. Capillary tubing of approximately 10 m (internal diameter: 1.0 mm) was used for mixing the column eluent with the post-column reagent before the detector. The post-column reagent was prepared by adding 10 mL of 6 nm phenolphthalein ethanol solution to 990 mL of 8 nm sodium bicarbonate aqueous solution, and this was adjusted to pH 10.5 by 1 m sodium hydroxide. The column eluent was 0.9% sodium chloride solution that was adjusted to pH 4.3 by acetic acid. The detector was set at 546 nm. A total of 40 μL of 20% trichloroacetic acid solution was added to 100 μL of plasma sample and carefully mixed. After mixing and centrifugation for 5 min (10000×g, 4°C), 40 μL of 1 m sodium carbonate solution was added to 80 μL of the supernatant. The sample was shaken and passed through a filter (Millex-HP PES-0.45 μm; Merck KGaA, Darmstadt, Germany) and 10 μL of filtrated sample was injected into the HPLC column. The flow rate of the column eluent was 0.6 mL/min and the flow rate of the post-column reagent was 0.6 mL/min. The retention time of HPBCD was approximately 14 min. The peak height was used to calculate HPBCD concentrations based on calibration curves of saline spiked with HPBCD.

Statistical Analysis Statistical analysis was performed using GraphPad Prism ver. 5.01 (GraphPad Software, San Diego, CA, U.S.A.). Survival data were analyzed using the Kaplan–Meier method, and the log-rank test was used to compare statistical significances. Multiple comparisons were performed to examine the statistical significance of the results. When uniform variance of the results was identified, the Kruskal–Wallis analysis, the differences were then examined by applying Dunn’s multiple test.

RESULTS Effects of HPBCD on Survival Time and Changes in Body Weight in Npc1−/− Mice First, we examined the dose responsiveness of the effects of HPBCD treatment on the lifespan of Npc1−/− mice. In the saline-treated (control) group, all of the mice died within 83 d and the median survival time was 77 d. A significant effect was not observed with 400 mg/kg HPBCD.
treatment (median survival, 79 d) compared with saline. However, 1000, 2000, and 4000 mg/kg HPBCD significantly prolonged survival time in mice compared with the saline group (Fig. 1). The median survival was 90, 89, and 94 d in the 1000, 2000, and 4000 mg/kg groups, respectively. There was no significant difference in survival between the 20000 mg/kg group (median survival, 58 d) compared with the saline group. However, some mice treated with 20000 mg/kg died in the early stage of treatment (40–60 d). Two mice in the 20000 mg/kg group lived for a long time (approximately 90–100 d).

Effects of HPBCD on Biological and Histological Parameters in Npc1<sup>−/−</sup> Mice We then examined the dose responsiveness of the effects of HPBCD treatment on biological and histological parameters in Npc1<sup>−/−</sup> mice. The ratio of liver to body weight and serum ALT levels were significantly higher in Npc1<sup>−/−</sup> mice compared with Npc1<sup>+/−</sup> and Npc1<sup>+/+</sup> mice groups (Figs. 2A, B). These high ratios of liver to body weight and serum ALT levels were attenuated by HPBCD treatment in a dose-dependent manner. Statistical significance was observed in the ratio of liver to body weight in the 4000 mg/kg group compared with the Npc1<sup>+/−</sup> saline group (Fig. 2A). Significant lowering effects in serum ALT levels were observed in the 2000 and 4000 mg/kg groups (Fig. 2B). However, there were no significant differences in the ratio of liver to body weight and serum ALT levels in the 20000 mg/kg group compared with the Npc1<sup>+/−</sup> saline group.

Total cholesterol content in the liver was higher in Npc1<sup>−/−</sup> mice compared with Npc1<sup>+/−</sup> and Npc1<sup>+/+</sup> mice. This high total cholesterol content in Npc1<sup>−/−</sup> mice was dose-dependently prevented by HPBCD treatment (Fig. 2C). Although there was little effect of 400 mg/kg treatment on total cholesterol content, significant effects were observed in the other HPBCD-treated groups. The fraction of esterified cholesterol in the liver was lower in Npc1<sup>−/−</sup> mice compared with Npc1<sup>+/−</sup> and Npc1<sup>+/+</sup> mice (Fig. 2D). Treatment with HPBCD increased the fraction of esterified cholesterol in the Npc1<sup>−/−</sup> liver in a dose-dependent manner. Statistical significance was observed in the 4000 mg/kg group compared with the Npc1<sup>−/−</sup> saline group. Representative pathohistological images are shown in Fig. 2E. Extensive vacuolated hepatocytes and Kupffer cells were observed in histological sections of saline-treated Npc1<sup>−/−</sup> mice compared with Npc1<sup>+/−</sup> and Npc1<sup>+/+</sup> mice. These pathohistological changes were dose-dependently attenuated in the HPBCD treatment groups. Although vacuolated hepatocytes and Kupffer cells were also reduced in the HPBCD treatment groups, hepatocellular necrosis was observed in the 20000 mg/kg group.

Changes in Serum HPBCD Concentrations in Npc1<sup>−/−</sup> Mice We examined the changes in serum HPBCD concentrations after HPBCD treatment (1000, 2000, and 4000 mg/kg) in Npc1<sup>−/−</sup> mice. As shown in Fig. 3, serum HPBCD concentrations were approximately 1200, 2000, and 2500 µg/mL at 0.5 h after administration of 1000, 2000, and 4000 mg/kg, respectively. Serum HPBCD concentrations were immediately reduced with time and were approximately 400–1600 µg/mL (0.29–1.14 mM) at 2 h after HPBCD injection.

Changes in Serum HPBCD Concentrations Following Intravenous Infusion to a Patient with NPC We measured serum HPBCD concentrations to evaluate pharmacokinetic characteristics of HPBCD in an NPC patient. The NPC patient (female, 5 years old, body height was 105 cm, and weight was 15.1 kg) was treated with HPBCD (40000 mg, intravenously administered for 8 h), and serum was collected at 2, 8, and 12 h after the start of the infusion. As shown in Fig. 4, serum HPBCD concentrations were 1295, 1756, and 90 µg/mL at 2, 8, and 12 h after the start of infusion. Serum HPBCD concentrations appeared to immediately begin to decrease with time after the end of HPBCD administration. The estimated pharmacokinetic parameters of the patient based on these values of serum HPBCD concentrations were as follows: systemic clearance, 198 mL/h/kg; volume of distribution, 266 mL/kg; and elimination half-life, 0.92 h. The graph in Fig. 4 shows the theoretical curve, assuming that HPBCD is rapidly distributed in the extracellular fluid, and then excreted at the rate of glomerular filtration, even in the patient with NPC. All three serum HPBCD concentrations that were observed in the NPC patient provided a good fit of the theoretical curve well (Fig. 4).

DISCUSSION

This study aimed to evaluate the effective dosage of HPBCD that can improve the survival time of Npc1<sup>−/−</sup> mice, and to measure serum HPBCD concentrations when treated with HPBCD in Npc1<sup>−/−</sup> mice. In addition, we determined serum HPBCD concentrations in an NPC patient who received intravenous HPBCD infusion and evaluated the pharmacokinetic characteristics of HPBCD in this patient. First, we showed that treatment of 1000, 2000, or 4000 mg/kg HPBCD (subcutaneously, once a week) significantly improved survival. All liver function parameters (unesterified and esterified cho-
Fig. 2. Dose Responsiveness of the Effects of HPBCD and Images of Hepatic Sections

Dose responsiveness of the effects of HPBCD on (A) liver/body weight ratio, (B) serum ALT levels, (C) total cholesterol content, and (D) percentage of esterified cholesterol in liver tissue. (E) Representative images of hepatic sections in Npc1−/− mice. Npc1+/+ and Npc1+/− mice were used as control animals. Npc1−/− mice were divided into the following groups: (1) Npc1−/− saline group; (2) 400 mg/kg group; (3) 1000 mg/kg group; (4) 2000 mg/kg group; (5) 4000 mg/kg group; (6) 20000 mg/kg group; (7) Npc1+/+ saline group; and (8) Npc1+/− saline group. We treated 6-week-old NPC mice with HPBCD or saline once a week until 8.5 weeks of age by subcutaneous injection (3 injections in total). Histological sections were stained with H&E. The arrow shown in the picture of HPBCD 20000 mg/kg treated group indicates hepatocellular necrosis. Scale bar: 100 µm. *p<0.05, **p<0.01 compared with the Npc1−/− saline group. ##p<0.01 compared with the Npc1+/+ saline group. Each bar represents the mean±S.E. (n=6).
lesterol content, relative liver weight, and serum ALT activity) were significantly attenuated by 4000 mg/kg HPBCD and in Npc1−/− mice compared with saline-treated mice. In addition, treatment of 2000 mg/kg HPBCD prevented the increase in unesterified cholesterol content in the liver and serum ALT activity. Aquil et al.15) examined the effective dosage of HPBCD on hepatic cholesterol synthesis activity 24 h after subcutaneous administration in 7-week-old Npc1−/− mice, and showed that the median effective dose was approximately 200 mg/kg. However, 400 mg/kg HPBCD-treated mice did not show any significant effects in this study. Based on these results, we consider that 1000 mg/kg HPBCD or higher is required for improving survival and liver pathophysiological changes in Npc1−/− mice.

Our previous study showed that the maximum nontoxic dose in Npc1−/− mice is 20000 mg/kg by a single subcutaneous injection in an acute toxic study.12) In the current study, although total cholesterol content in the liver was normalized with 20000 mg/kg HPBCD when subcutaneously administered every week, there was no improvement in survival, serum ALT levels, liver/body weight ratio, or liver esterified cholesterol content in Npc1−/− mice. This lack of finding may be because of the toxicity of multiple administrations of 20000 mg/kg HPBCD.

In our study, serum HPBCD concentrations at effective dosages (1000, 2000, and 4000 mg/kg, subcutaneously, once a week) that could improve survival were approximately 0.9–1.8 mM (1200–2500 µg/mL) at 0.5 h and 0.3–1.2 mM (400–1600 µg/mL) at 2 h after HPBCD injection. Peake and Vance6) showed that 0.1 and 1 mM HPBCD effectively reduced stored cholesterol in isolated primary culture cells from Npc1−/− mice without any cytotoxic action. Tamura and Yui16) also reported similar data in their in vitro experiment using NPC patient-derived dermal fibroblasts. The effective concentrations observed in these in vitro studies appear to be in agreement with those observed in our in vivo study. Based on these results, we suggest that the effective concentration of HPBCD against the NPC disease state is between 0.1–1 mM. However, subcutaneously-injected HPBCD appears to be promptly eliminated from the blood. In this study, the elimination half-life of HPBCD was approximately 1 h. Therefore, HPBCD may be completely cleared within 12 h after injection of Npc1−/− mice. Aquil et al.15) showed that the elimination half-life of 14C-labeled HPBCD (4000 mg/kg) injected subcutaneously was 1.6 h in Npc1−/− mice, which is consistent with our results. Some previous reports have also demonstrated that just a single or weekly subcutaneous injection of HPBCD can significantly prolong life-span and improve pathophysiological changes in Npc1−/− mice.17–19) These findings suggest that transient increases in HPBCD, rather than maintaining blood levels, is required to exert effectiveness of HPBCD against NPC disease.

Matsuo et al.45) showed the effectiveness of intravenous HPBCD therapy in two NPC patients. These patients were treated with approximately 2500 mg/kg of HPBCD (intravenously administered for 8 h) twice per week over 1 year without severe adverse reactions, and hepatosplenomegaly and central nervous dysfunction were improved. In our study, we measured serum HPBCD concentrations during this therapy in one patient. We observed that serum HPBCD concentrations were similar to the effective concentrations observed in in vitro or in vivo. Some previous reports have shown that HPBCD, a cyclic oligosaccharide with high water solubility, is distributed to the extracellular fluid, and is eliminated from blood to urine by renal excretion without hepatic metabolism in rodents and humans.18,19) In our study, the pharmacokinetic
parameters of HPBCD, such as systemic clearance (2.89 L/h) and volume of distribution (0.26 L/kg), were in agreement with parameters of physiological function, such as estimated glomerular filtration rate (2.65 L/h) and extracellular fluid volume (0.25 L/kg), respectively. These results suggest that a large portion of HPBCD is rapidly distributed to the extracellular fluid and excreted at the rate of glomerular filtration in NPC patients, as well as in healthy humans. However, a small portion of HPBCD appears to be incorporated into the intracellular compartment to act as a cholesterol carrier instead of NPC1. Therefore, dose adjustment appears to be required according to renal function to achieve a therapeutic concentration and to avoid toxicity during HPBCD therapy in NPC patients.

Chemical properties, such as the ability for inclusion complex formation, are different among HPBCDs with different DSs. Therefore, information on the DS appears to be important for evaluating the therapeutic effects of HPBCD against NPC manifestation. Lie et al. reported that subcutaneous administration of a single dose (4000 mg/kg) of HPBCD (average DS of 4.5 or 5.6) to Npc1−/− mice at 7 d of age markedly prolonged lifespan, and no difference was observed between the two HPBCD preparations. In some previous studies, HPBCD with DSs of approximately 4.2–5.6 appears to have been used for evaluation of its therapeutic effects on NPC manifestation. Therefore, we used HPBCD with a comparable DS to previous studies in this study. The DS of HPBCD might affect the therapeutic potential against NPC manifestation. In this study, we preliminarily examined the effects of three HPBCD preparations that had different average DSs (2.8, 4.4, and 7.4) on the cholesterol content in Npc1-deficient cells. Significant differences were not observed among the three preparations on the cholesterol-decreasing effects (Supplemental Fig. 1). Although these results suggest that the difference in DS, at least in the range of approximately 3 to 7, does not affect the therapeutic potential of HPBCD; further study is warranted to clarify this issue.

Although the precise mechanisms of the therapeutic effects of HPBCD against NPC disease are unclear, HPBCD may alter membrane structures within the late endosome/lysosome and improve cholesterol trafficking in NPC-deficient cells, thus exerting therapeutic potential. Rosenbaum et al. suggested that endocytosed cyclodextrin can reduce cholesterol storage by acting from inside endocytic organelles rather than by removing cholesterol from the plasma membrane. Taylor et al. reported that HPBCD did not increase cholesterol in plasma or urine of treated Npc1−/− mice. This finding suggests that HPBCD does not carry sterol from the cell membrane into the bloodstream for ultimate urinary excretion. They also demonstrated that HPBCD promptly decreased the rate of cholesterol synthesis and increased esterified cholesterol levels in tissues of Npc1−/− mice. They advocated that HPBCD functions in cells of Npc1−/− mice by rapidly liberating lysosomal cholesterol for normal sterol processing within the cytosolic compartment. In our study, we also measured serum free and esterified cholesterol levels after HPBCD or saline treatment in Npc1−/− mice (Supplemental Fig. 2). Although 1000 or 2000 mg/kg of HPBCD did not show any effects, 4000 mg/kg or greater of HPBCD treatment reduced serum free and esterified cholesterol levels in Npc1−/− mice. These changes in serum cholesterol levels were not likely to be a good measure of the therapeutic effect of HPBCD. At least, HPBCD treatment did not increase serum cholesterol levels. Our study results of the changes in serum cholesterol levels are consistent with the results by Taylor et al.

In this study, information obtained from Npc1−/− mice and in an NPC patient could be useful for HPBCD therapy. However, the present study has the following limitations. First, the appropriate frequency and method of HPBCD administration are unknown. Previous reports have shown that subcutaneous administration of HPBCD (4000 mg/kg) every week is effective in Npc1−/− mice. In the current study, we found that subcutaneous injection every week of HPBCD could not maintain serum concentrations for a long time, but survival was clearly improved. However, there are no data on the effects of other frequencies of administration (e.g., every day, twice a week, or continuous infusion) of HPBCD. Further study is warranted to evaluate the most effective administration method of HPBCD to achieve the maximum therapeutic potential of HPBCD in Npc1−/− mice and patients. Second, the route of administration of HPBCD was different between animal and human experiments. In our study, the NPC patient was treated with HPBCD by intravenous infusion and serum HPBCD concentrations were determined. However, we evaluated the effective serum concentrations of HPBCD in Npc1−/− mice when administered subcutaneously according to the method of previous reviews. Therefore, factors that can affect pharmacodynamics and/or pharmacokinetics of HPBCD, such as the absorption process, should be considered in our data of Npc1−/− mice. The changes in serum HPBCD concentrations tended to be non-linear in the 4000 mg/kg-treated group compared with the 1000 and 2000 mg/kg-treated groups. This finding may be due to saturation and/or inefficient absorption from hypodermal tissue. We administered the HPBCD solution at the same volume among the three groups (20 µL/g). Therefore, the concentration of HPBCD solution used in the 4000 mg/kg-treated group was 150 mM, and this was higher than the concentrations in the 1000 and 2000 mg/kg-treated groups (37.5 and 75 mM, respectively). In addition, the viscosity of HPBCD solution in the high-dose groups (4000 and 20000 mg/kg groups) was likely to be high. We observed gel-like formation in hypodermal tissue after treatment with the high doses (4000–20000 mg/kg) in mice (Supplemental Fig. 3). This may also have affected the absorption of HPBCD from hypodermal tissue in Npc1−/− mice. Therefore, further detailed pharmacokinetic studies of HPBCD in Npc1−/− mice are required to resolve this issue.

In summary, this study shows that weekly subcutaneous injection of 1000, 2000, or 4000 mg/kg HPBCD can improve survival of Npc1−/− mice. Symptoms of NPC, liver cholesterol sequestration and injury, are significantly attenuated by 4000 mg/kg in Npc1−/− mice. Serum HPBCD concentrations at effective dosages are approximately 0.9–1.8 mM (1200–2500 µg/mL) at 0.5 h after subcutaneous injection, and blood HPBCD concentrations are immediately eliminated in Npc1−/− mice. In addition, serum HPBCD concentrations with treatment of approximately 2500 mg/kg HPBCD twice a week in a patient with NPC are consistent with the effective concentrations observed in vivo using Npc1−/− mice. Additionally, systemic clearance and the volume of distribution are in agreement with the glomerular filtration rate and extracellular fluid volume, respectively. Although further studies are required, the pharmacokinetic parameters obtained in this study...
will provide a rational basis for providing an optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.

Acknowledgments We are grateful to Yuka Horikoshi, Shiori Takeuchi, Yumiko Hirose, Makiko Taguchi, and all of the staff of the Division of Reproductive Engineering, Center for Animal Resources and Development, Kumamoto University, for breeding the mice. We also gratefully acknowledge financial support from the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Numbers 23590642 and 26460221 to Irie T.).

Conflict of Interest Tetsumi Irie, Yoichi Ishitsuka, Muneki Matsuo, Naomi Nakagata, Keichi Motoyama, Hitodetsu Arima, and Sakiko Mochinaga received the research grants from the Japan Society for the Promotion of Science. Tetsumi Irie received HPBCD as a gift from Nihon Shokuhin Kako Co., Ltd. Koki Wada is an employee of Nihon Shokuhin Kako Co., Ltd. Yuta Tanaka, Yusei Yamada, Koki Shiraishi, Yushiro Uchio, Yuki Kondo, Toru Takeo, Taishi Higashi, Katsumi Higaki, and Kousaku Ohno have no conflict of interest in this study.

Supplementary Materials The online version of this article contains supplementary materials.

REFERENCES


